179 related articles for article (PubMed ID: 29900654)
1. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?
Kondili LA; Robbins S; Blach S; Gamkrelidze I; Zignego AL; Brunetto MR; Raimondo G; Taliani G; Iannone A; Russo FP; Santantonio TA; Zuin M; Chessa L; Blanc P; Puoti M; Vinci M; Erne EM; Strazzabosco M; Massari M; Lampertico P; Rumi MG; Federico A; Orlandini A; Ciancio A; Borgia G; Andreone P; Caporaso N; Persico M; Ieluzzi D; Madonia S; Gori A; Gasbarrini A; Coppola C; Brancaccio G; Andriulli A; Quaranta MG; Montilla S; Razavi H; Melazzini M; Vella S; Craxì A;
Liver Int; 2018 Dec; 38(12):2190-2198. PubMed ID: 29900654
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
European Union HCV Collaborators
Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
[TBL] [Abstract][Full Text] [Related]
3. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
Kondili LA; Blach S; Razavi H; Craxì A
Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
[TBL] [Abstract][Full Text] [Related]
4. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
[TBL] [Abstract][Full Text] [Related]
5. A micro-elimination approach to addressing hepatitis C in Turkey.
Idilman R; Razavi H; Robbins-Scott S; Akarca US; Örmeci N; Kaymakoglu S; Aygen B; Tozun N; Güner R; Bodur H; Lazarus JV
BMC Health Serv Res; 2020 Mar; 20(1):249. PubMed ID: 32209103
[TBL] [Abstract][Full Text] [Related]
6. Challenges on the achievement of World Health Organization goals for HCV elimination in Italy: need for a Regional programmatic approach on screening and linkage to care. Commentary.
Kondili LA; Aghemo A; Andreoni M
Ann Ist Super Sanita; 2021; 57(3):201-204. PubMed ID: 34554113
[TBL] [Abstract][Full Text] [Related]
7. A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions.
Kondili LA; Andreoni M; Alberti A; Lobello S; Babudieri S; De Michina A; Merolla R; Marrocco W; Craxì A
BMC Infect Dis; 2022 Jan; 22(1):58. PubMed ID: 35038987
[TBL] [Abstract][Full Text] [Related]
8. Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression.
Kondili LA; Andreoni M; Alberti A; Lobello S; Babudieri S; Roscini AS; Merolla R; Marrocco W; Craxì A
Epidemics; 2021 Mar; 34():100442. PubMed ID: 33607538
[TBL] [Abstract][Full Text] [Related]
9. Is global elimination of HCV realistic?
Calvaruso V; Petta S; Craxì A
Liver Int; 2018 Feb; 38 Suppl 1():40-46. PubMed ID: 29427499
[TBL] [Abstract][Full Text] [Related]
10. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT
PLoS One; 2021; 16(9):e0257369. PubMed ID: 34529711
[TBL] [Abstract][Full Text] [Related]
11. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
12. Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
Schorr O; Blach S; Thurnheer C; Ruis C; Dufour JF
PLoS One; 2022; 17(8):e0272518. PubMed ID: 35960770
[TBL] [Abstract][Full Text] [Related]
13. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
[TBL] [Abstract][Full Text] [Related]
14. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis G; Razavi H; Hatzakis A
J Gastroenterol Hepatol; 2017 Feb; 32(2):466-472. PubMed ID: 27403912
[TBL] [Abstract][Full Text] [Related]
15. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
Müllhaupt B; Bruggmann P; Bihl F; Blach S; Lavanchy D; Razavi H; Robbins Scott S; Semela D; Negro F
PLoS One; 2018; 13(12):e0209374. PubMed ID: 30596701
[TBL] [Abstract][Full Text] [Related]
16. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
[TBL] [Abstract][Full Text] [Related]
17. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
18. ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria.
Schwarz C; Bauer D; Dorn L; Jachs M; Hartl L; Chromy D; Weseslindtner L; Pfisterer N; Hennlich B; Stückler A; Strassl R; Voill-Glaninger A; Hübl W; Willheim M; Köhrer K; Jansen-Skoupy S; Tomez S; Krugluger W; Madl C; Schwarz M; Balcar L; Semmler G; Brinkmann L; Burghart L; Antonitsch L; Weidinger G; Riedl F; Laferl H; Kurteva V; Traugott M; Hind J; Wenisch C; Aburaia A; Sebesta C; Schmid D; Rothweiler S; Remetic J; Gschwantler M; Maieron A; Reiberger T
Wien Klin Wochenschr; 2024 May; 136(9-10):278-288. PubMed ID: 37773541
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
20. An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
Shiha G; Soliman R; Mikhail NNH; Easterbrook P
J Hepatol; 2020 Apr; 72(4):658-669. PubMed ID: 31734097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
